zh-twzhen
zh-twzhen

The Company’s 2025Q2 consolidated financial statements have been approved by the Board of Directors

2022

Date

Title

2022-08-26

The trading of Oneness securities in centralized securities exchange market follows Announcement or Notice of Attention to Trading Information

>
2022-08-23

Oneness submitted an IND to US FDA for a phase I clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai)

>
2022-08-20

US FDA notified today that 510(k) Premarket Notification of Bonvadis, the wound care topical cream was substantially equivalent.

>
2022-08-11

The Company’s 2022Q2 consolidated financial statements have been approved by the Board of Directors

>
2022-07-16

News-Diabetes: Better Relief for Ulcerated Feet On the Horizon

>
2022-07-04

The Drug Administration of Vietnam has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon

>
2022-06-22

Oneness announces the information about the investor’s conference of 2022 Q2.

>
2022-06-02

The findings of the MoA studies on Fespixon(ON101) under collaboration with TMU and NYCU have been accepted and published by a renown SCI journal, JID Innovations

>
2022-05-26

Oneness Biotech Co.,LTD receives a China patent on antagonistic PDL1 aptamers.

>
2022-05-24

The Annual General Shareholders’ Meeting approved the removal of non-competition restriction on the newly-elected director.

>
2022-05-24

By-election of one director of the board in 2022 shareholders’ meeting

>
2022-05-24

Oneness announce the important resolutions of the 2022 Annual General Shareholders’ Meeting

>
2022-05-11

The Company’s 2022Q1 consolidated financial statements have been approved by the Board of Directors

>
2022-05-02

Oneness received the notification by the international CRO on the unblinded data of FB825 Phase 2a study in moderate-to-severe atopic dermatitis in the U.S.

>
2022-04-29

News-Oneness Ranked among Top 5% in the 8th Corporate Governance Evaluation

>